Company News 30 Sep 2020 Landmark Publication Points to IC14 Target in ALS-MND ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with… Implicit Bioscience
Company News 03 Jun 2020 FDA approves COVID-19 study On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300… Implicit Bioscience
Company News 16 Dec 2019 New research links IC14 target to dementia New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and… Implicit Bioscience
Company News 17 Sep 2019 Australian Immunotherapy Selected for Revolutionary US Clinical Trial Platform Debut An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54… Implicit Bioscience
